Literature DB >> 8612590

Synergistic enhancement of both initiation and elongation by acidic transcription activation domains.

W S Blair1, R A Fridell, B R Cullen.   

Abstract

The effects of activation domain synergy on transcription initiation and elongation have been examined utilizing a system that permits the targeting of a defined number of activation modules to promoter DNA. As predicted, incremental increases in targeted activation potential were found to result in corresponding increases in transcription initiation. Surprisingly, however, transcriptional processivity, and hence mRNA synthesis, required a threshold level of activation domain synergy that exceeded the level required for at least modest levels of transcription initiation. The degree to which transcriptional processivity was enhanced was shown to depend on the quantity of activation modules targeted to the promoter DNA, rather than the quality. While the RNA-sequence specific HIV-1 Tat trans-activator was also shown to enhance processivity in this assay system, Tat differed from DNA-sequence specific activation domains in exerting a more dramatic effect on the efficiency of transcript elongation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612590      PMCID: PMC450077     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  37 in total

1.  A nuclear translational block imposed by the HIV-1 U3 region is relieved by the Tat-TAR interaction.

Authors:  M Braddock; A M Thorburn; A Chambers; G D Elliott; G J Anderson; A J Kingsman; S M Kingsman
Journal:  Cell       Date:  1990-09-21       Impact factor: 41.582

Review 2.  Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins.

Authors:  P J Mitchell; R Tjian
Journal:  Science       Date:  1989-07-28       Impact factor: 47.728

3.  A functional ribonucleoprotein complex forms around the 5' end of poliovirus RNA.

Authors:  R Andino; G E Rieckhof; D Baltimore
Journal:  Cell       Date:  1990-10-19       Impact factor: 41.582

4.  Separation of DNA binding from the transcription-activating function of a eukaryotic regulatory protein.

Authors:  L Keegan; G Gill; M Ptashne
Journal:  Science       Date:  1986-02-14       Impact factor: 47.728

5.  The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.

Authors:  M H Malim; J Hauber; S Y Le; J V Maizel; B R Cullen
Journal:  Nature       Date:  1989-03-16       Impact factor: 49.962

6.  A vector for expressing GAL4(1-147) fusions in mammalian cells.

Authors:  I Sadowski; M Ptashne
Journal:  Nucleic Acids Res       Date:  1989-09-25       Impact factor: 16.971

7.  Use of eukaryotic expression technology in the functional analysis of cloned genes.

Authors:  B R Cullen
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

8.  Expression and characterization of the trans-activator of HTLV-III/LAV virus.

Authors:  C M Wright; B K Felber; H Paskalis; G N Pavlakis
Journal:  Science       Date:  1986-11-21       Impact factor: 47.728

9.  A mammalian RNA polymerase II holoenzyme containing all components required for promoter-specific transcription initiation.

Authors:  V Ossipow; J P Tassan; E A Nigg; U Schibler
Journal:  Cell       Date:  1995-10-06       Impact factor: 41.582

10.  Elements required for transcription initiation of the human U2 snRNA gene coincide with elements required for snRNA 3' end formation.

Authors:  N Hernandez; R Lucito
Journal:  EMBO J       Date:  1988-10       Impact factor: 11.598

View more
  14 in total

1.  The role of AHA motifs in the activator function of tomato heat stress transcription factors HsfA1 and HsfA2.

Authors:  P Döring; E Treuter; C Kistner; R Lyck; A Chen; L Nover
Journal:  Plant Cell       Date:  2000-02       Impact factor: 11.277

2.  Transfer of Tat and release of TAR RNA during the activation of the human immunodeficiency virus type-1 transcription elongation complex.

Authors:  N J Keen; M J Churcher; J Karn
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

3.  CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription.

Authors:  C Suñé; T Hayashi; Y Liu; W S Lane; R A Young; M A Garcia-Blanco
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

4.  Combinatorial Gene Regulation through Kinetic Control of the Transcription Cycle.

Authors:  Clarissa Scholes; Angela H DePace; Álvaro Sánchez
Journal:  Cell Syst       Date:  2016-12-29       Impact factor: 10.304

5.  Effects of heterologous downstream sequences on the activity of the HIV-1 promoter and its response to Tat.

Authors:  M E Greenberg; M B Mathews
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

Review 6.  Considerations of transcriptional control mechanisms: do TFIID-core promoter complexes recapitulate nucleosome-like functions?

Authors:  A Hoffmann; T Oelgeschläger; R G Roeder
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

7.  Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.

Authors:  P D Bieniasz; T A Grdina; H P Bogerd; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

8.  Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF.

Authors:  I J McEwan; J Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

9.  The minimal transactivation region of Saccharomyces cerevisiae Gln3p is localized to 13 amino acids.

Authors:  V Svetlov; T G Cooper
Journal:  J Bacteriol       Date:  1997-12       Impact factor: 3.490

10.  Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat.

Authors:  P D Bieniasz; T A Grdina; H P Bogerd; B R Cullen
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.